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Background: Iron is essential not only for erythropoisis but also for several bioenergetics’ processes in myocardium.
Hepcidin is a well-known regulator of iron homeostasis. Recently, researchers identified low hepcidin was
independently associated with increased 3-year mortality among systolic heart failure patients. In addition, our
previous in vivo study revealed that the left ventricular mass index increased in chronic kidney disease patients with
lower serum hepcidin. We hypothesize that hepcidin interacts with the apoptotic pathway of cardiomyocytes
during oxidative stress conditions.
Methods: To test this hypothesis, human cardiomyocytes were cultured and treated with ferrous iron. The possible
underlying signaling pathways of cardiotoxicity were examined following knockdown studies using siRNAs of
hepcidin (siRNA1 was used as a negative control and siRNA2 was used to silence hepcidin).
Results: We found that ferrous iron induces apoptosis in human cardiomyocytes in a dose-dependent manner. This
iron-induced apoptosis was linked to enhanced caspase 8, reduced Bcl-2, Bcl-xL, phosphorylated Akt and GATA-4.
Hepcidin levels increased in human cardiomyocytes pretreated with ferrous iron and returned to non-iron treated
levels following siRNA2 transfection. In iron pretreated cardiomyocytes, the siRNA2 transfection further increased
caspase 8 expression and decreased the expression of GATA-4, Bcl-2, Bcl-xL and phosphorylated Akt than iron
pretreatment alone, but caspase 9 levels remained unchanged.
Conclusions: Our findings suggest that hepcidin can rescue human cardiomyocytes from iron-induced apoptosis
through the regulation of GATA-4/Bcl-2 and the extrinsic apoptotic pathway.
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Iron is essential not only for erythropoiesis but also for
several bioenergetic processes in the myocardium [1].
Cardiac muscle iron overload leads to systolic and dia-
stolic abnormalities, cardiac hypertrophy, and thus myo-
cardial dysfunction in animal models [2]. At the molecular
level, excess extracellular iron in heart muscle is thought
to induce the formation of reactive oxygen species (ROS),
such as superoxide and hydroxyl radicals via the Haber
Weiss and Fenton reactions. The overproduction of these
ROS, in turn, increases the susceptibility to cardiac injury* Correspondence: cylin@mail.cmuh.org.tw; 27509@cch.org.tw
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unless otherwise stated.and cell death [2]. In contrast, chronic iron deficiency
may, by itself, reduce exercise capacity and cause ultra-
structural alterations in cardiomyocytes [3]. Indeed, Dong
et al. found that in iron-deficient rats, heart weight and left
ventricle dimension were increased, as well as mitochon-
drial swelling and sarcomere disorganization, which may
collectively lead to cardiac hypertrophy [4].
Hepcidin, a recently discovered 25-amino acid peptide
that contains four disulfide bonds, was first identified in
human urine and plasma [5]. The pivotal role of hepcidin
in iron homeostasis was established in transgenic mouse
models and in human diseases that result because of either
its excess or deficiency [6,7]. Further studies found that
hepcidin regulates iron homeostasis by binding to and in-
ducing the internalization and degradation of ferroportin,
the sole cellular iron efflux channel in iron-transporting
cells [8]. Elevated hepcidin inhibits the release of storedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion. The net effect of which is greater intracellular iron
storage, along with less iron dietary absorption and circu-
lating availability [9].
However, an increasing number of studies show that
iron deficiency itself inhibits the expression of hepcidin
and its release into the circulation [10-12]. Weber and
colleagues reported that hepcidin levels in the lower tertile
were strongly associated with iron deficiency [13]. Using
multivariable Cox models, Jankowska et al. found that low
hepcidin was independently associated with increased
3-year mortality among systolic heart failure (HF) pa-
tients [14]. These authors also found a gradual reduc-
tion in serum hepcidin levels during the natural course
of HF, in accompaniment with depleted iron stores
(low serum ferritin) and iron-restricted erythropoiesis
(reduced hemoglobin, high red blood cell distribution
width [RDW]).
Six GATA transcription factors have been identified in
vertebrates and are divided into two subclasses based
on their expression patterns. GATA-1, −2, and −3 are
prominently expressed in hematopoietic cell lineages,
whereas GATA-4, −5, and −6 are expressed in various
mesoderm- and endoderm-derived tissues such as the
heart, liver, lung, gonad, and gut [15,16]. Evidence for
the role of GATA factors in the regulation of apoptosis
was initially generated in studies of GATA-1-deficient
precursor cells that were found to undergo apoptosis
[17]. GATA-4 is a survival factor in terminally differen-
tiated cardiomyocytes [18,19] and may be an essential
component of the adaptive response of the adult heart
[19]. In our previous study, we found that activation of
ERK can protect against pro-apoptotic stimulants [20].
Notably, GATA-4 contains putative ERK phosphorylation
sites, and suppression of the ERK/GATA-4 pathway in-
duces cardiomyocyte apoptosis [20]. Notably, GATA-4 is
enriched in cardiac tissue where it is essential for various
cardiomyocyte physiological and adaptive responses. More-
over, an early event in doxorubicin (an antitumor drug)-
induced cardiotoxicity is GATA-4 depletion, which in turn
results in cardiomyocyte apoptosis [18,19]. GATA-4 has
also been shown to upregulate transcription of the anti-
apoptosis genes Bcl-2 and Bcl-XL in cardiomyocytes
[20,21]. Thus these studies support that GATA-4 plays a
central role in regulating the survival of cardiomyocytes
through regulation of apoptosis.
Bcl-2 protein family members are best characterized
proteins for their direct involvement in the regulation of
apoptosis [22]. Bcl-2 and its closest homologues, Bcl-xL
and Bcl-w, potently inhibit apoptosis in response to
many cytotoxic insults. Bax and Bak, on the other hand,
are well known proapoptotic members of the Bcl-2 pro-
tein family. Conditions that induce myocardial stress
cause complex alterations in levels of Bcl-2 familyproteins [23]. Cardiac Bcl-2 gene expression has been
shown to be regulated by GATA-4 both in vitro and
in vivo [21]. During apoptosis, the 14 members of the
caspase family in mammals are produced in cells as cata-
lytically inactive zymogens and must undergo proteolytic
activation. Caspases involved in apoptosis are generally
divided into two categories: the initiator caspases, which
include caspase-2, −8, −9, and −10, and the effector cas-
pases, which include caspase-3, −6, and −7 [24].
Cardiomyocyte apoptosis can result in a loss of con-
tractile tissue, compensatory hypertrophy of myocardial
cells, reparative fibrosis, and heart failure. Bulvik et al.,
showed that myocardial protection by ischemic precon-
ditioning (IPC) is mediated by a transient 'iron-signal' in
concert with ferritin accumulation [25]. Our recent cross-
sectional observational study in chronic kidney disease
(CKD) patients [26] demonstrated that after adjustment
for BMI, age, anemia, lipid profiles and blood pressure,
there was a negative correlation between serum hepcidin
and left ventricular mass. However, the knowledge of
the hepcidin’s impact on cardiomyocytes from previous
studies is limited.
Thus, we postulate that changes to hepcidin levels may
regulate the apoptotic pathway of cardiomyocytes follow-
ing oxidative stress. To test this hypothesis, human cardio-
myocytes were cultured and treated with ferrous iron, and
the effects of siRNA-mediated knockdown of hepcidin, as
well as possible underlying signaling pathways of cardio-
toxicity, were examined. In our knowledge, this is the first
study to transfect human cardiomyocytes with hepcidin
siRNA and understand the effect this has on GATA-4.
Methods
The study was approved by the Institutional Review
Board of the Changhua Christian Hospital, Taiwan. Under
the approval of the Institutional Review Board of the
China Medical University Hospital, Taiwan, human car-
diomyocytes were obtained from myocardial ventricular
resections of patients who underwent cardiac surgery,
as described previously [20]. All subjects gave written
and informed consent to participate.
Cardiomyocyte culture
Human cardiomyocytes were cultured for 8 days, during
which the culture medium was replaced every third day.
Endogenous CAPON protein expression in cultured cardi-
omyocytes was detected by immunofluorescent staining
and confocal microscopy [20]. We also measured electro-
physiological characteristics of cultured cardiomyocytes,
including action potential duration (APD) and peak
L-Type calcium current (IcaL) [27]. Both APD and
peak L-Type calcium current (IcaL) were APD10, APD50,
APD75 and APD90: 95.4 ± 10.6, 289.2 ± 15.6, 308.2 ± 15.4,
and 318.4 ± 16.4 ms, respectively, with a peak IcaL density
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cardiomyocytes incubated with 20 μM iron displayed
hypertrophy, while cardiomyocyte necrosis occurred at a
dose of 100 μM iron [28]. Cultured human cardiomyocytes
were treated with ferrous iron (500 microg/mL, 18 h) then
transfected with siRNA against hepcidin. Forty-eight hours
later, cellular lysates were prepared as previously described
[29], and proteins were resolved on SDS-polyacrylamide
gels and transferred to Immobilon polyvinyldifluoride
(PVDF) membranes. Membranes were blocked with 4%
(w/v) BSA for 1 h at 22.2°C and probed with rabbit anti-
human Ab against hepcidin (Abcam, Abgent, San Diego,
CA), Akt (Cell Signaling Technology, Beverly, MA),
Caspase 8 (Millipore Corp., Billerica, MA, USA), pro-
caspase 9 (Cell Signaling Technology), Bcl-2 (Santa,
Cruz, CA), Bcl-xL (Santa Cruz) and β-actin (Sigma)
(1/1000) for 1 h at room temperature. Protein expression
was visualized by ECL using Kodak X-OMAT LS film
(Eastman Kodak, Foster City, CA, USA). Quantitative data
were obtained using a computing densitometer and Image
Quant software.
Bromodeoxyuridine (BrdU) assay
Cardiomyocyte proliferation was determined using the
BrdU assay. Briefly, in a 96-well microplate, 2 × 105 car-
diomyocytes/well were incubated in 100 μL of culture
media and exposed to different concentrations of ferrous
iron, or Doxorubicin (DOXO, 0.5 μM) as a positive con-
trol. Our preliminary data (not shown) for the time course
experiment indicated that the incubation time for the
maximal effect of ferrous iron on human cardiomyocytes
was 18 h. Cells were further incubated with 10 μL of
1 mM BrdU/mL and fluorescent anti-BrdU antibody for
15 min (BrdU Flow kits, BD Pharmingen, San Jose, CA,
USA), then resuspended for flow cytometry analysis.
Apoptosis assays
Flow cytometry
Apoptosis was quantitatively gauged by detecting phos-
phatidylserine exposure on cell membrane with Annexin
V staining [20]. Cells were simultaneously stained with
Annexin V-FITC (25 ng/ml; green fluorescence, R&D
Systems, Minneapolis, MN) and dye exclusion (propidium
iodide, 20 mg/ml, red fluorescence). Data were obtained
by flow cytometry analysis with FACS-SCAN (Becton-
Dickinson, Heidelberg, Germany) FACS Canto in cell pop-
ulations from which debris was gated out and analyzed.
Comet assay
The comet assay (single-cell gel electrophoresis) is an
uncomplicated and sensitive method for measuring de-
oxyribonucleic acid (DNA) strand breaks in eukaryotic
cells. Cardiomyocytes (approximately 5 × 103 cells/mL)
were incubated with DOXO or phosphodiesterase (PDE)during peritonitis for 24 h at 37°C, isolated, then examined
for DNA damage using the comet assay as previously de-
scribed [30]. Briefly, treated cells were embedded in situ in
1% (w/v) agarose, then placed in lysis solution for 30 min.
Cell nuclei were subsequently separated by electrophoresis
for 20 min at 1 V/cm, followed by staining with PI and
visualization under a fluorescence microscope.
RNA isolation and reverse transcription
RNA was extracted from cells using RNAzol B (Tel-Test,
Inc., Friendswood, Tex.), and was then converted to cDNA
by reverse transcription. Samples were stored at −70°C
until ready for analysis by PCR.
Real-time PCR with SYBR green
For real-time PCR, 5 μL of cDNA (1–10 ng) was mixed
with SYBR green PCR core reagent or master mix reagent
(Applied Biosystems, CA, USA). The thermal cycling con-
ditions were determined according to the rules of the
‘Thermal cycling parameters for primer optimization’.
Each RNA sample was also analyzed for β-actin expres-
sion, which served as an internal control for correcting
relative specific gene expression levels. Primers were de-
signed using Primer Express Primer Design software, and
are as follows:
Bcl-2: sense primer: ATGTGTGTGGAGAGCGTCAA
antisense primer: ATCACCAAGTGCACCTACCC
Bcl-xL: sense primer: ACAGCAGCAGTTTGGATGC
antisense primer: TGGGATGTCAGGTCACTGAA
GATA-4: sense primer: AGCTCCTTCAGGCAGTGAGA
antisense primer: CTGTGCCCGTAGTGAGATGA
β-actin: sense primer: CAGGTATGCACCCAGAGTGA
antisense: GATATGGAGAAGATTTGGCA
According to the amplification plot, the cycle number
over the threshold equals the Ct value. The Ct value of
the non-template control was 45. The relative expression
ratio among untreated RNA and different RNA samples
could be thus calculated by 2-Ct.
Western blotting
For western blotting, 10–50 μg of protein extracts were
separated using 10–12% SDS-polyacrylamide gel electro-
phoresis, transferred to nitrocellulose (PVDF) membranes,
then blocked overnight with 1 × tris buffered saline buffer
containing 5% (w/v) skim milk. Membranes were next
incubated with optimal concentrations of primary anti-
bodies: anti-GATA-4 mAb (Abcam), and anti-β actin
mAb (Sigma) all diluted in blocking buffer. Membranes
were washed and then incubated with appropriate second-
ary antibodies (goat anti-mouse mAb conjugated with
HRP), and visualized using the enhanced chemilumines-
cence detection kit (Perkin Elmer, MA, USA). The anti-
bodies for GATA-4 (1:100) and Bcl-XL (1:100) were
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(1:1000) was purchased from Cell Signaling (CA, USA).
siRNA transfection
Two pairs of small-interfering RNAs (siRNA1 and siRNA2)
were synthesized by Invitrogen Life Technology (Invitro-
gen). siRNA2 was employed to knock-down hepcidin
levels and siRNA1 was injected s the negative control.
Cultured human cardiomyocytes were transfected with
each siRNA (20 μM) using Lipofectamine RNAiMAX
(Invitrogen) as per the manufacturer’s instructions. After
48 h, protein was extracted for western blot analysis.
Statistical analyses
Values are expressed as the mean ± standard deviation
(SD). Parameters between groups were compared using
the Jonckheere Terpstra or Kruskal-Wallis test for non-
parametric continuous data, or the independent t-test for
parametric data. Statistical analysis was performed via
SPSS for Windows software, version 15.0. A P-value < 0.05
was considered statistically significant.
Results
Ferrous iron induces cell death in human cardiomyocytes
Cardiac cell death is believed to be a major contributor
in the development and progression of myocardial dys-
function [31]. To assess whether ferrous iron treatment
induces cardiac death, cell viability of cardiomyocytes
treated with ferrous iron, or DOXO as a positive control,
was evaluated by BrdU flow cytometry. The BrdU assay
revealed that ferrous iron induced human cardiomyocyte
cell death in a dose-dependent manner (Figure 1). As
expected, DOXO also induced cardiotoxicity.
Ferrous iron induces apoptosis in human cardiomyocytes
To further explore whether ferrous iron accumulation
induces human cardiomyocyte apoptosis, we assessedFigure 1 Cell proliferation of human cardiomyocytes treated
with different concentrations of ferrous iron. Doxorubicin
(DOXO, 0.5 μM) was used as a positive control. Data are expressed
as the mean ± SD of six independent experiments.apoptotic cell death using Annexin V-FITC and flow cy-
tometry. As above, DOXO (0.5 μM) was used as a posi-
tive control. After cell incubation with ferrous iron for
18 h, apoptosis was observed. Higher concentrations of
ferrous iron resulted in greater numbers of damaged
cells (Table 1). Using the comet assay (Figure 2), we also
monitored the extent of cardiomyocyte apoptosis follow-
ing pretreatment with ferrous iron and more severe car-
diomyocyte apoptosis damage following transfection with
siRNA2 to knockdown hepcidin expression.
Ferrous iron suppresses GATA-4 expression in human
cardiomyocytes
The transcription factor GATA-4 is a well-known specific
myocardial survival factor [32]. To characterize the mech-
anisms underlying ferrous iron-induced apoptosis in hu-
man cardiomyocytes, mRNA expression and protein levels
of GATA-4 were measured. GATA-4 mRNA expression
was decreased in a dose-dependent manner after in-
cubation with ferrous iron (Figure 3a). Western blots
of nuclear GATA-4 protein expression also showed a
dose-dependent decrease in response to ferrous iron
in cardiomyocytes (Figure 3b).
Silencing of hepcidin induced apoptosis in iron-induced
human cardiomyocytes
To further explore the mechanisms of ferrous iron-
induced apoptosis, other well-known apoptotic markers
were examined by western blotting. After cardiomyocyte
treatment with ferrous iron (500 mg/mL, 18 h; middle
column of Figure 4), in comparison to non-iron medium,
there was increased expression of both hepcidin and
cleaved caspase 8, and a significant decrease in Bcl-2,
Bcl-xL, phosphorylated Akt and GATA-4 expression
levels. Following hepcidin siRNA2 transfection and
treatment with ferrous iron (right column of Figure 4),
hepcidin protein returned to non-iron treated levels.Table 1 Effect of different doses of ferrous iron on
apoptosis in cultured human cardiomyocytes
Ferrous Iron (μg/ml) % apoptosis (mean ± SD)
0 1.0 ± 2.2
10 1.1 ± 2.3
50 4.2 ± 2.1
100 7.6 ± 2.5
250 8.4 ± 2.3
500 11.2 ± 2.1
Positive control: DOXO (0.5 μM) 10.1 ± 2.2
Positive control: medium + DOXO (0.5 μM): 10.1 ± 2.2%.
Cultured human cardiomyocytes were incubated with medium alone or in
combination with ferrous iron at the indicated concentrations for 18 h to
reach the maximal effect of ferrous iron. Medium plus DOXO (0.5 μM) was
used as a positive control. Following the maximal effect of ferrous iron, cells
were stained with annexin V-FITC and apoptosis analysis was determined by
FACS. Each value represents the mean ± SD from six independent experiments.
Figure 2 Comet assay: effect of silencing hepcidin on ferrous iron-induced cardiomyocyte apoptosis. siRNA2 was employed to knock-down
hepcidin levels and siRNA1 was injected as a negative control. Cultured human cardiomyocytes, pretreated with ferrous iron (500 microg/mL, 18 h),
were transfected with each siRNAs (20 μM, 48 h). DNA damage was then determined by the comet assay. Ferrous iron-free treated cells were used as
the control.
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significantly increased and protein expression levels
of Bcl-2, Bcl-xL, phosphorylated Akt and GATA-4 were
significantly suppressed when compared with the non-
iron medium group.
Following treatment with ferrous iron and siRNA2
(right column of Figure 4), cleaved caspase 8 levels were
higher and protein levels of Bcl-2, Bcl-xL, phosphorylated
Akt and GATA-4 were significantly lower than treatment
with ferrous iron only (middle column of Figure 4). ThereFigure 3 Effects of ferrous iron on GATA-4 m-RNA and protein
levels in cardiomyocytes. GATA-4 mRNA expression was decreased
in a dose-dependent manner after incubation with ferrous iron
(Figure 3a). Western blots of nuclear GATA-4 protein expression
also showed a dose-dependent decrease in response to ferrous iron
in cardiomyocytes (Figure 3b). Cultured human cardiomyocytes were
treated with different concentrations of ferrous iron. Doxorubicin
(DOXO, 0.5 μM) was used as a positive control. Data are normalized to
β-actin, and are expressed as the mean ± SD of six independent
experiments.was no significant difference among the conditions with
respect to caspase 9 protein levels.
Discussion
In the present study, we have demonstrated for the first
time that transfection of human cardiomyocytes with
hepcidin siRNA can downregulate anti-apoptotic GATA-
4/Bcl-2. By contrast, hepcidin siRNA augmented protein
expression of pro-apoptotic caspase 8. This finding was
consistent with our earlier published clinical study which
found that there was a significant negative correlation
between serum hepcidin levels with either left ventricu-
lar mass (LVM) or the left ventricular mass index
(LVMI) in CKD patients [26]. We also found that ferrous
iron-induced human cardiomyocyte apoptosis was associ-
ated with decreased protein expression of GATA-4, Bcl-2,
and Bcl-xL, and phosphorylated Akt. In addition, ferrous
iron increased the expression of hepcidin and caspase 8 in
human cardiomyocytes.
Iron ions stored within the ferritin molecule are
redox-inactive and cannot catalyze the generation of free
radicals [33]. By contrast, excessive extracellular iron in
heart muscle is thought to induce the formation of ROS.
Therefore, ferritin is assumed to play an important cyto-
protective role against free radical formation by control-
ling free cytosolic iron content [34]. Moreover, it has
been shown that ROS formation, amplified by labile and
redox-active iron ions, increases the susceptibility to
cardiac injury and cell death [35]. Indeed, in the BrdU
cell viability study, we showed that ferrous iron-induced
human cardiomyocyte cell death was dose-related. Con-
sistent with our finding, Munoz et al. showed that differ-
ent iron concentrations exhibit diverse effects on cultured
cardiomyocytes, whereby either its excess or deficiency
inflicts myocardial damage [28].
There is convincing evidence that apoptosis contributes
to the progression of heart failure [36]. Inflammatory me-
diators and cytokines have been cited as playing a role in
cardiomyocyte apoptosis and clinical cardiac dysfunction
[37]. More recently, experiments demonstrated that
Figure 4 Hepcidin knockdown by siRNAs alters the apoptotic protein expression profile. siRNA2 was employed to knock-down hepcidin
levels. Cultured human cardiomyocytes were transfected with each siRNAs (20 μM). After 48 h, proteins were extracted for western blot analysis.
The protein expression of caspase-8, Bcl-2, Bcl-xL and phosphorylated Akt, were measured by western blotting. Cultured human cardiomyocytes
were pretreated with ferrous iron (500 mg/mL) only (lane 2) and in combination with siRNA2 for silencing hepcidin (lane 3). Cells cultured in
ferrous iron-free medium were also analyzed (lane 1). Quantitative densitometry was performed and a histogram was developed showing protein
expression relative to total protein. Data are expressed as the mean ± SD of six independent experiments. P-values are indicated.
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daunorubicin and doxorubicin, cause cardiomyopathy
and also induce cardiac myocyte apoptosis [38]. Using
doxorubicin as a positive control, we demonstrated that
greater ferrous iron levels resulted in more apoptosis
in human cardiomyocytes. Cardiogenesis is known to
be enhanced in embryonic stem cells overexpressing
GATA-4, while its depletion results in apoptosis [39].
Survival factors of cardiomyocytes, such as hepatocyte
growth factor and endothelin-1, activate GATA-4 to
protect the heart against oxidative stress [19]. Ourresults also show that exogenous iron can downregu-
late the expression of GATA-4 mRNA and protein
levels in a dose-dependent manner.
Importantly, following human cardiomyocyte pretreat-
ment with ferrous iron, we noted that the expression
levels of hepcidin and caspase 8 increased, while those
of Bcl-2, Bcl-xL, and phosphorylated Akt significantly
decreased. From the study, we suggest that the pro-
apoptotic pathway contributes to the iron-associated
cardiomyopathy. In the heart, hepcidin is an intrinsic
cardiac hormone which has a predominantly local effect
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myocardium after myocardial infarction showed particular
upregulation of hepcidin [41]. The authors speculated that
upregulation of hepcidin may reduce iron toxicity and
thus infarct size expansion in an infarcted heart [41]. Our
present findings seem to be consistent with these assump-
tions that beyond iron regulation, hepcidin expression in
the heart could impact on heart function. In the present
study, however, we did not link Akt activation and the
GATA-4-Bcl-2/Bcl-xL pathway.
Island et al. reported that GATA-4 may participate in
the control of hepcidin expression and that the alteration
of its expression could contribute to the development of
iron-related disorders [42]. Previous research [43] has
shown that overexpression of Bcl-2 attenuates myocardial
apoptosis. Similarly, in an in vivo study we found that hep-
cidin may be involved in cardioprotection [26]. In the
present study, we found that the combined treatment of
human cardiomyocytes with hepcidin siRNA and ferrous
iron led to the increased synthesis of cleaved caspase 8,
while that of hepcidin, as well as other anti-apoptotic
proteins, were significantly suppressed. These findings
indicate that silencing hepcidin could downregulate anti-
apoptotic protein synthesis and provoke cardiomyocyte
death. Indeed, evaluation of DNA damage by Comet assay
confirmed the negative impact of hepcidin siRNA on
cardiomyocytes.
In addition, following silencing of hepcidin mRNA ex-
pression, the synthesis of caspase 8 was enhanced. By
contrast, caspase 9 levels did not significantly change.
As known, the extrinsic apoptotic pathway is mediated by
caspase 8, which is first activated by the death receptors
and, in turn, activates caspase 3. In the intrinsic pathway,
caspase 9 is first activated by mitochondria-released cyto-
chrome C [44]. Based on these observations, we propose
the extrinsic apoptotic pathway could be the target for
cardioprotection by hepcidin.
There were several limitations in our studies: (1) Given
that only caspase 9 was monitored, it is difficult to attri-
bute the observed apoptosis to the extrinsic pathway
alone. To rule out any involvement of the intrinsic path-
way, we need to monitor at least cytochrome c release or
inhibit caspase 8 activation to determine if cell death could
be completely inhibited. (2) The knockdown of hepcidin
resulted in an increase in apoptosis, but suggested that
hepcidin played a protective role. If we could show that
over-expression of hepcidin resulted in an increase in
Bcl-2, GATA-4, Bcl-xl etc. and that would greatly en-
hance our work.
In conclusion, this study demonstrates that hepcidin
acts as a novel survival factor for human cardiomyo-
cytes through the regulation of GATA-4/Bcl-2 and the
extrinsic apoptotic pathway. These results comple-
ment our earlier clinical findings that serum hepcidinis significantly negatively correlated with LVM and
LVMI [26].
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